TheMercenary • Jan 16, 2009 2:43 pm
Workers ages 50 to 64 who get their annual flu shots miss less work and experience less of a productivity drop-off than those who don't, according to a new study, findings that might help public officials lift immunization rates among this age-group.I wonder if workers in that age group are more confident, and in a better financial position, to miss work?
TheMercenary;526835 wrote:Update: Virginia is getting hammered.
TheMercenary;526835 wrote:Update: Virginia is getting hammered.
TheMercenary;526835 wrote:Update: Virginia is getting hammered.
http://www.cdc.gov/flu/weekly/WeeklyFluActivityMap.htm
http://www.cdc.gov/flu/weekly/
wolf;526986 wrote:The Virginia concentration could be the result of commuters to DC. People go to the doctor near home, not near work, in most cases.
wolf;526986 wrote:The Virginia concentration could be the result of commuters to DC. People go to the doctor near home, not near work, in most cases.
INTERPRETATION: The effect of influenza vaccination on the risk of pneumonia in elderly people during influenza seasons might be less than previously estimated.source
CONCLUSIONS: The 51% reduction in mortality with vaccination initially observed in patients with pneumonia who did not have influenza was most likely a result of confounding. Previous observational studies may have overestimated mortality benefits of influenza vaccination.source
Recent excess mortality studies were unable to confirm a decline in influenza-related mortality since 1980, even as vaccination coverage increased from 15% to 65%.source
CONCLUSION: In 2 seasons with suboptimal antigenic match between vaccines and circulating strains, we could not demonstrate VE in preventing influenza-related inpatient/ED or outpatient visits in children younger than 5 years. Further study is needed during years with good vaccine match.source
source
In children and adults the consequences of influenza are mainly absences from school and work, however the risk of complications is greatest in children and people over 65 years old...
It was surprising to find only one study of inactivated vaccine in children under two years, given recent recommendations to vaccinate healthy children from six months old in the USA and Canada. If immunisation in children is to be recommended as public-health policy, large-scale studies assessing important outcomes and directly comparing vaccine types are urgently required.
CDC has antigenically characterized 1,817 seasonal human influenza viruses [1,049 influenza A (H1), 196 influenza A (H3) and 572 influenza B viruses] collected by U.S. laboratories since October 1, 2008, and 233 novel influenza A (H1N1) viruses.
All 1,049 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 2008-09 influenza vaccine (A/Brisbane/59/2007). One hundred eighty-eight (96%) of 196 influenza A (H3N2) viruses tested are related to the A (H3N2) vaccine component (A/Brisbane/10/2007) and eight viruses (4%) tested showed reduced titers with antisera produced against A/Brisbane/10/2007.
All 233 novel influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) reference virus selected by WHO as a potential candidate for novel influenza A (H1N1) vaccine.
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-eight (12%) of 573 influenza B viruses tested belong to the B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 504 (88%) viruses belong to the B/Victoria lineage and are not related to the vaccine strain.
Data on antigenic characterization should be interpreted with caution given that antigenic characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference ferret antisera and results may not correlate with clinical protection against circulating viruses provided by influenza vaccination.
Annual influenza vaccination is expected to provide the best protection against those virus strains that are related to the vaccine strains, but limited to no protection may be expected when the vaccine and circulating virus strains are so different as to be from different lineages, as is seen with the two lineages of influenza B viruses. Antigenic characterization of novel influenza A (H1N1) viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with seasonal influenza vaccine.
Thanks, we keep a large bottle of purell hand sanitizer on the kitchen counter and clorox wipes at every sink. I have felt achy but so far no real S&S. Probably a strong immunity from years of exposure to stuff at work.glatt;583099 wrote:THE flu, or just the flu?
Hope they feel better soon. Wash your hands a lot.
Over 99% of all subtyped influenza A viruses being reported to CDC were novel influenza A (H1N1) viruses.